Generations to come

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The FDA has set a goal date of Aug. 31, 2025.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

A prediction of 2025 by Doug Mirsky, Ph.D., vice president of healthcare delivery at Digital Medicine Society.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

A prediction for this year by Shawn Gremminger, president and CEO of National Alliance of Healthcare Purchaser Coalitions.

Jerilyn Arneson, Pharm. D, co-founder and officer of the National Association of Medication Access & Patient Advocacy, gives her 2025 prediction.